5 European Projects Found
Searched on 125080 European Projects
FINISHED
Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes (RATHER)
Start date: Jan 1, 2011, End date: Dec 31, 2016,
"Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biologic ...
Read Project
8
Partners Participants
FINISHED
WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients (WINTHER)
Start date: Mar 1, 2013, End date: Feb 28, 2015,
Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patientsCurrent medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, ...
Read Project
12
Partners Participants
FINISHED
Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)
Start date: Jan 1, 2011, End date: Dec 31, 2014,
Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Read Project
11
Partners Participants
FINISHED
OVErcoming Resistance to anti-HER2 therapy (OVER-HER2)
Start date: Jan 1, 2011, End date: Dec 31, 2014,
"HER2 is a membrane receptor tyrosine kinase overexpressed in 30% of breast tumors and results in an aggressive clinical course. Anti-HER2 therapies including monoclonal antibodies (trastuzumab) and small-molecule tyrosine kinase inhibitors (lapatinib) are active and have improved survival of patients with HER2 overexpressing breast cancer. However, the emergence of primary or acquired resistance ...
Read Project
2
Partners Participants
FINISHED
Role of Notch signaling pathway in Glioma Stem Cells (Notch pathway in GSC)
Start date: Jun 1, 2012, End date: Sep 20, 2014,
Glioblastoma multiforme (GBM) is the most common malignant intracranial tumor in adults. Despite the knowledge of the genetic alterations associated to GBM and the improvement in neurosurgery and chemo- and radiotherapy, little improvement has been achieved in the median survival. Recently, glioma stem cells (GSCs) have been identified to be responsible of the origin, recurrence and drug resistanc ...
Read Project
